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Abstract
Background: Triple-negative breast cancer (TNBC) lacks specific therapeutic target and limits to chemotherapy and
is essential to develop novel therapeutic regimens. Increasing studies indicated that tamoxifen, a selective estrogen
receptor modulators (SERMs), has anti-tumor therapeutic effect in estrogen receptor α (ERα)-negative tumor. Here,
we determined whether autophagy was activated by tamoxifen in TNBC cells. Moreover, CSC-3436 displayed strong
and selective growth inhibition on cancer cells. Next, we investigated the anti-proliferation effect of combination of
CSC-3436 plus tamoxifen on cell death in TNBC cells.
Results: Our study found that tamoxifen induces autophagy in TNBC cells. Endoplasmic reticulum stress and AMPK/
mTOR contributed tamoxifen-induced autophagy. Interestingly, in combination treatment with CSC-3436 enhanced
the anti-proliferative effect of tamoxifen. We found that CSC-3436 switched tamoxifen-induced autophagy to apoptosis
via cleavage of ATG-5. Moreover, AMPK/mTOR pathway may involve in CSC-3436 switched tamoxifen-induced
autophagy to apoptosis. The combination of tamoxifen and CSC-3436 produced stronger tumor growth inhibition
compared with CSC-3436 or tamoxifen alone treatments in vivo.
Conclusion: These data indicated that CSC-3436 combined with tamoxifen may be a potential approach for
treatment TNBC.
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Background
Hormone receptors (estrogen and progesterone receptors)
and human epidermal growth factor receptor (HER2)
status are biological markers and are widely accepted in
terms of their clinical importance in breast cancer. Triple-
negative breast cancer (TNBC) is defined by a lack expres-
sion of all three receptors (estrogen, progesterone and
HER2) and represents approximately 15–20 % of all breast
cancers [1–3]. TNBC patients are high risk of early recur-
rence and high incidence of visceral and central nervous
system (CNS) metastases [4]. TNBC lacks specific
therapeutic target and limits to chemotherapy. However,
the data about TNBC therapy issue are insufficient as
present. It is essential to develop novel therapeutic
regimens.
Tamoxifen has represented the widely used therapy
with its abundant, mature safety data in clinical hor-
mone therapy [5]. Tamoxifen belongs to selective estro-
gen receptor modulators (SERMs) and acts as antagonist
that complete with estradiol binding to estrogen recep-
tor α (ERα) and then could modulate its transcriptional
capabilities for ERα-positive breast cancer patients [6, 7].
There have been increasing studies indicated that
tamoxifen has anti-tumor therapeutic effect in both
ERα-positive breast cancer and ERα-negative tumors
e.g. glioma, melanoma, colon cancer and pancreatic
carcinoma though growth inhibition, apoptosis and
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autophagy, suggesting that tamoxifen could be an an-
ther choice for ERα-negative tumor treatment [8].
In principle, autophagy is a highly-conserved catabolic
in eukaryotic cells and it maintains cellular homeostasis
through the balance of cellular metabolism and the
clearance of aggregated or misfolded proteins [9].
Autophagy-deregulated related to many diseases, such as
neurodegeneration, heart disease and cancer develop-
ment. Briefly, the process of autophagy is featured by the
formation of double-membrane cytosolic vesicles,
known as autophagosomes. The autophagosomes fuse
with lysosomes to form autolysosome, in which lyso-
somal hydrolases digest the cargo to metabolites that are
released back into the cytosol for recycling [10]. It well
known that the effect of the formation of autophago-
some include autophagy-related gene (ATG) 5, Beclin-1
(known as ATG6) and the conversion of LC3-I to LC3-II
through proteolytic cleavage and lipidaation is considerate
a hallmark of mammalian autophagy [11–13]. Autophagy
plays a dual role in cancer process dependents on various
cases. Autophagy plays pro-death response by autophagic
cell death. On the contrary, autophagy exhibits cytopro-
tective response undendoplasmic reticulum stress condi-
tions involving nutritional starvation of amino acids or
fatty acids, hypoxia, oxidative stress, damaged mitochon-
dria and chemotherapies [11, 14].
Previous studies indicated that cytoprotective autophagy
provided cancer cell chemoresistance and that autophagy
suppression enhanced therapy-induced apoptosis and pro-
liferation inhibition [15–19]. The relationship between
autophagy and apoptosis is unclear. A rationale for the
use of autophagy inhibitors in combination with chemo-
therapy agents is considered a better approach to improve
efficacy of anticancer therapeutics. Therefore, investigat-
ing the autophagy inhibition enhance cancer cell chemo-
sensitivity is considered a better approach to improve
efficacy of anticancer therapeutics during the tumor
development.
In our previous studies, CSC-3436 displays strong and
selective growth inhibition on the NCI60 cell lines by
inhibiting tubulin polymerization [20]. The IC50 of CSC-
3436 in different types of breast cancer cell lines includ-
ing TNBC (MDA-MB-231, MDA-MB-468, BT-549, and
BT-20), ERα-positive (MCF-7 and T47D) and HER-2
amplified (BT-474) narrow down to nanomolar. In the
present study, we found that tamoxifen induced cytopto-
tective role in TNBC cells. Interestingly, CSC-3436 sen-
sitized TNBC cells to tamoxifen.
Methods
Cell culture
TNBC cell, MDA-MB-231, is mesenchymal phenotype
with high vimentin expression but undetectable E-
cadherin expression. MDA-MB-231 was grown in
DMEM/F12 (Invitrogen Corporation, Carlsbad, CA,
USA). Medium was supplemented with 10 % fetal bovine
serum (FBS), 2 mM L-glutamine, 100 U penicillin and
100 μg streptomycin (Invitrogen Corporation, Carlsbad,
CA, USA). All cell lines were grown in a humidified in-
cubator at 37 °C under 5 % CO2 in air.
Reagents and antibodies
CSC-3436 was resuspended in DMSO. 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT),
3-methyladenine [3-MA (autophagy inhibitor)] and pri-
mary antibody β-actin were purchased from Sigma
Chemical Co. (St. Louis, Mo, USA). Salubrinal (endo-
plasmic reticulum stress inhibitor), ISP-1 (ceramide in-
hibitor), primary antibodies cleavage ATG-5 and primary
GRP78 were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Primary antibodies Beclin-1,
LC3-I/II, ATG5-ATG12 complex, p-AMPK, AMPK, p-
mTOR, mTOR and β-actin were purchased from Cell
Signaling Technology (Beverly, MA, USA). Secondary
antibodies, HRP-conjugated Goat anti-Mouse IgG and
Goat anti-Rabbit IgG, were obtained from Millipore
(Billerica, MA, USA).
Supravital cell staining with acridine orange (AO)
detection
To detect acidic vesicular organelles (AVOs), cells were
stained with 1 mg/mL AO (Sigmal Chemical Co.,) for a
period 20 min. Cells were then analyzed with a fluores-
cent microscope (Nikon TE2000-U) using an excitation
filter of 502 nm and an emission filter of 525 nm.
Monodansylcadaverine staining
After various treatments for autophagy induction, cells
were stained with 5 mM monodansylcadaverine (MDC;
Fluka) for a period 15 min. Cells were than analyzed a
fluorescent microscope (Nikon TE2000-U) using an
excitation filter of 360 nm and an emission filter of
525 nm.
Cell viability assay
MDA-MB-231 cells were seeded in a 24-well plate (2 ×
104 cells/well) overnight, and then were treated with in-
dicated times of CSC-3436 with or without tamoxifen or
tamoxifen only. Cell viability was examined by the MTT
assay. Briefly, 80 μL MTT solution (2 mg/mL) was added
to each well to make a final volume of 500 μL and incu-
bated for 1.5 h at 37 °C. The supernatant was aspirated,
and the MTT-formazan crystals formed by metabolically
viable cells were dissolved in 500 μL of DMSO. Finally,
the absorbance at O.D. 570 nm was detected by
enzyme-linked immunosorbent assay (ELISA) reader.
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Western blot analysis
Cells were seeded onto a 100-mm culture dishes (1 ×
106/dish) containing 10 % FBS. Cells were than treated
with various agents as indicated in the figure captions.
After treatment, the total proteins were extracted by
adding 50 μL of gold lysis buffer (50 mM Tris–HCl,
pH 7.4; 1 mM NaF; 150 mM NaCl; 1 mM EGTA; 1 mM
phenylmethylsulfonyl floride; 1 % NP-40; and 10 mg/mL
leupeptin) to the cell pellets. Lysate proteins were deter-
mined by the Lowry protein assay (Bio-Rad Laborator-
ies). The samples (50 μg of proteins) of total cell lysates
were resolved by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and (SDS-PAGE), transferred to
nitrocellulose membranes. Membranes were blocked
with 5 % BSA (Sigma, St. Louis, MO, USA) for 1 h at
room temperature, and probed with primary antibody
for 1.5 h at room temperature or overnight at 4 °C
followed by HRP-conjugated appropriated secondary
antibodies.
Cell cycle analysis
MDA-MB-231 cells were suspended with ice-cold PBS
and fixed in 75 % ethanol at −20 °C for 18 h. After fix-
ation, the cells were washed twice, incubated in 0.5 mL
of 0.5 % Triton X-100/PBS at 37 °C for 30 min with
1 mg/mL of RNase A, and stained with 0.5 mL of 50 μg/
mL propidium iodide (PI) for 10 min. Fluorescence
emitted from the PI-DNA complex was analyzed at
488 nm/600 nm (excitation/emission wavelength) by a
fluorescence activated cell sorter (FACScan flow cytome-
try). The population of nuclei in each phase of the cell
cycle was determined using Cell Quest and analyzed by
WinMDI software programs (BectonDickinson, San Jose,
California).
RNA interference
We used the MicroPorator, a pipette-type electropor-
ation system, (Digital Bio Tech, Korea) to transfect cells.
The RNA interference reagents were obtained from the
National RNA interference Core Facility located at the
Institute of Molecular Biology/Genomic Research
Centre, Academia Sinica. The human library is referred
to as TRC-Hs 1.0. ATG5 clone is identified as short hair-
pin RNA (shRNA) TRCN0000330394.
Animal studies
Female BALB/c nude mice (18–20 g; 6–8 weeks of age)
were purchased from the National Animal Center
(Taipei, Taiwan) and maintained in pressurized venti-
lated cage in accordance with institutional regulations.
Animal studies involving mice were approved by the In-
stitutional Animal Care and Use Committee (IACUC) of
China Medical University and Reg. No. 101-15-N. All
efforts were made to minimize animal suffering and to
reduce the number of animals sacrificed.
MDA-MB-231 cells (3 × 106) were inoculated subcuta-
neous into the right flank of the mice. Seven days after
inoculation, when tumor volumes were larger than
100 mm3, the mice were divided into indicated groups
(nine mice per group) and treated daily with vehicle
alone and various doses of indicated drugs. The mice
were weighed, and their tumors were measured using
calipers twice per week by using a digital caliper. The
tumor volume was calculated using the following for-
mula: (width × length2)/2. On the final day of treatment,
the mice were sacrificed; the tumors were excised,
weighed, and sectioned; the tumor sections were embed-
ded in an optimal cutting temperature (OCT) com-
pound and frozen at −70 °C.
Statistical analysis
One-way analysis of variance (ANOVA) was used for the
comparison of more than two mean values. Results rep-
resent at least two to three independent experiments.
Results with a P value less than 0.05 were considered
statistically significant. *, p < 0.05.
Results
Tamoxifen induces autophagy in TNBC cells
Tamoxifen is a well-known agent to trigger ERα-positive
MCF-7 breast cells autophagy [21]. To determine
whether autophagy is activated by tamoxifen in ERα-
negative breast cells, we harvested TNBC MDA-M231
cells at the indicated times after exposure to 5 μM tam-
oxifen. LC3 is essential for autophagosome formation
and as an autophagy marker [11]. Western blot analysis
of LC3-I and LC3-II was determined by western blotting.
Tamoxifen triggered the conversion of LC3 from LC3-I
to LC3-II in MDA-MB-231 cells (Fig. 1a). MDA-MB-
231 cells treated with tamoxifen, rapamycin (autophagy
inducer), and 3-MA (autophagy inhibitor) to confirm
tamoxifen-induced LC3-II accumulation. 3-MA sup-
pressed partly tamoxifen-induced LC3-II accumulation
(Fig. 1b). To investigate whether two autophagy-related
proteins, Beclin-1 and ATG5-ATG12 complex, were in-
volved in tamoxifen-induced autophagy. MDA-MB-231
cells were treated with tamoxifen at various concentra-
tions (0, 2.5, 5 and 7.5 μM) for 48 h, or at the indicated
times (0, 12, 24 and 48 h) after exposure to 5 μM
tamoxifen. Tamoxifen treated increased Beclin-1 and
ATG5-ATG12 complex protein levels both in dose- and
time-dependent manner (Fig. 1c and d).
Tamoxifen-induced AV formation and MDC-stained
autophagosomes/autophagic bodies
To observe autophagic vacuoles (AV) formation, MDA-
MB-231 cells were treated with indicated times (0, 12,
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24 and 48 h) of tamoxifen and analyzed cells by using
confocal microscopy. The number of LC3(+) vacuoles
continued to increase for 12 to 48 h after initiation of
tamoxifen treatment (Fig. 2a). MDC is an autofluores-
cent agent and as a specific autophagolysosome marker
[22] to analyze the autophagic process. MDA-MB-231
cells were treated with 5 μM tamoxifen at 0, 12, 24 and
48 h and analyzed cells by using microscopy. Arrows in-
dicated MDC-stained autophagosomes/autophagic bod-
ies. The AV continued to increase for 24 to 48 h after
initiation of tamoxifen treatment (Fig. 2b). Taken to-
gether, tamoxifen induces ERα-negative breast cancer
cells autophagy.
Tamoxifen-induced autophagy related with endoplasmic
reticulum stress and AMPK/mTOR pathway
Previous studies indicated that endoplasmic reticulum
stress and ceramide contributed to autophagy induction
[23, 24]. Therefore, we determined whether endoplasmic
reticulum stress and ceramide generation participated in
autophagy induction by tamoxifen in MDA-MB-231
cells. MDA-MB-231 cells were treated with several times
(0, 12, 24 and 48 h) after exposure to 5 μM tamoxifen.
GRP78, the endoplasmic reticulum stress marker, was
up-regulation (Fig. 3a). We next determined the effect of
the endoplasmic reticulum stress inhibitor salubrinal on
tamoxifen-induced autophagy by analyzing LC3-II accu-
mulation. Salubrinal inhibited tamoxifen-induced LC3-II
accumulation. We also examined the effect of the cer-
amide inhibitor ISP-1 on tamoxifen-induced autophagy
but LC3-II accumulation didn’t significantly change
(Fig. 3b). Autophagy is promoted by AMPK, which is a
key energy sensor to regulate energy homeostasis and
also inhibits the mammalian target of rapamycin
(mTOR) [25]. MDA-MB-231 cells were treated with sev-
eral times (0, 12, 24 and 48 h) after exposure to 5 μM
tamoxifen and p-AMPK was up-regulation and p-mTOR
was down-regulation (Fig. 3c). Taken together, endoplas-
mic reticulum stress and AMPK/mTOR contributed
tamoxifen-induced autophagy.
CSC-3436 plus tamoxifen enhanced cell death in
MDA-MB-231 cells
Firstly, we examined the effect of CSC-3436 on cell
growth inhibition in MDA-MB-231 cells. MDA-MB-231
cells were treated with CSC-3436 (Fig. 4a) at various
concentrations (25, 50, 100, 200 and 400 nM) for 48 and
72 h. CSC-3436 induced growth inhibition both in dose-
and time-dependent manner (IC50 = 205 ± 3.21 for 48 h,
IC50 = 148 ± 2.31 for 72 h, respectively) (Fig. 4b). Next,
we investigated the anti-proliferation effect of CSC-3436,
tamoxifen, or combination of CSC-3436 plus tamoxifen
on cell death in MDA-MB-231 cells. The combination
treatment with CSC-3436 enhanced the anti-
proliferative effect of tamoxifen (Fig. 4c). The PI staining
indicated that the proportion of cells in apoptosis in
Fig. 1 Tamoxifen induces autophagy in MDA-MB-231 cells. a, c MDA-MB-231 cells were incubated with tamoxifen (5 μM) for 12, 24 and 48 h. Cells
were then harvested and lysed for the detection of LC3I/II, Beclin-1, ATG5-ATG12 complex and β-actin. b MDA-MB-231 cells were incubated with
rapamycin, tamoxifen, and 3-MA for 24 h. Cells were then harvested and lysed for the detection of LC3-I/II and β-actin. d MDA-MB-231 cells were
incubated with various concentrations (0, 2.5, 5 and 7.5 μM) for 48 h. Beclin-1, ATG5-ATG12 complex and β-actin were determined by
western blotting
Wu et al. Journal of Biomedical Science  (2016) 23:60 Page 4 of 10
MDA-MB-231 cells treated with CSC-3436 plus tamoxi-
fen was higher as compared with tamoxifen treated
alone (Fig. 4d). To test whether CSC-3436 plus tamoxi-
fen enhanced apoptosis in MDA-MB-231 cells, we con-
ducted Western blotting. Our result indicated that the
cleavage patterns of PARP and caspase-3 were observed
in the combination of CSC-3436 plus tamoxifen
(Fig. 4e). These data indicated that CSC-3436 switched
tamoxifen-induced autophagy to apoptosis.
ATG-5 and AMPK/mTOR pathway involved in CSC-3436
switched tamoxifen- induced autophagy to apoptosis
Autophagy under various stressful conditions could play
a pro-survival or pro-death role [11]. ATG-5 is required
for the generation of autophagosome in autophagy
process [26]. To clarify the role of ATG-5 in tamoxifen-
induced autophagy, we knocked down ATG-5 expression
with shATG5 in MDA-MB-231 cell and examined the
cell viability by MTT assay. ATG-5-deficient MDA-MB-
231 cells exhibited that CSC-3436 plus tamoxifen treated
reduced higher cell viability than tamoxifen or CSC-
3436 treated alone (Fig. 5a). Previous report indicates
that cleavage of ATG-5 involved in autophagy switch to
apoptosis process [23, 27]. We investigated whether
CSC-3436 switched tamoxifen-induced autophagy to
apoptosis via cleavage of ATG-5. We performed western
blotting assay to measure the cleavage of ATG-5. CSC-
3436 alone or CSC-3436 plus tamoxifen exhibited the
ATG-5 cleavage product (Fig. 5b). We also examined the
effect of CSC-3436 on tamoxifen-regulated p-AMPK
and p-mTOR. CSC-3436 inhibited tamoxifen-induced
up-regulation of p-AMPK slightly and down-regulation
of p-mTOR protein level expressions (Fig. 5c). Taken
together, the cleavage of ATG-5 and AMPK/mTOR
pathway may involve in CSC-3436 switched
tamoxifen-induced autophagy to apoptosis.
Fig. 3 Tamoxifen-induced autophagy is mediated through
endoplasmic reticulum stress and AMPK/mTOR signaling. MDA-MB-231
cells were incubated with 5 μM tamoxifen for 12, 24 and 48 h. Cells
were then harvested and lysed for the detection of a GRP78 and
c p-AMPK, AMPK, p-mTOR, mTOR and β-actin. b MDA-MB-231 cells
were in the presence of tamoxifen (5 μM), salubrnal (5 μM) and/or
ISP-1(10 μM) for 48 h followed by analysis of LC3 expression by
western blotting
Fig. 2 AO and MDC for autophagy detection in MDA-MB-231 cells.
a Immunofluorescence microscopy of acridine orange (AO)-stained
MDA-MB-231 cells treated with tamoxifen for 0, 12, 24 and 48 h. b
Monodansylcadaverine (MDC)-labeled vesicles (indicated by arrows)
were incubated by rapamycin in MCF-7 (as a positive control), 5 μM
tamoxifen for 0, 12, 24 and 48 h in MDA-MM-231 cells
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In vivo efficacy of the combination of tamoxifen and
CSC-3436 in MDA-MB-231 tumor xenograft model
To further check the in vivo relevance of the above ob-
servations, we examined the antitumor activity of the
combinatorial treatment with CSC-3436 and tamoxifen
in nude mice bearing MDA-MB-231 tumor xenografts
(starting mean tumor volume, 100 ± 5 mm3). The tumor
bearing mice were either treated oral administration
with vehicle, CSC-3436 (10, 20 and 40 mg/kg) or CSC-
3436 (5, 10 and 20 mg/kg) combined with tamoxifen
(2 mg/kg). There was no significant change in body
weights compared with the vehicle-treated group in all
treatments (Fig. 6a). Previous study indicated that tam-
oxifen treatment alone was disappointed to anti-tumor
activity of MDA-MB-231 tumor xenograft model [28].
Treatment with CSC-3436 alone induced a dose
dependent inhibition in comparison to the vehicle-
treated group. Tamoxifen combined with CSC-3436 at
low (5 mg/kg), medium (10 mg/kg) and high (20 mg/kg)
doses exhibited much more significant tumor growth
inhibition (Fig. 6b). Apparently, CSC-3436 (5 mg/kg)
plus tamoxifen-group reached similar tumor volume
Fig. 4 Combinatorial treatment with CSC-3436 and tamoxifen induced stronger G2/M phase arrest and anti-proliferative ability. a Chemical structure of CSC-
3436. b MDA-MB-231 cells were treated with several concentrations (0, 25, 50, 100, 200 and 400 nM) CSC-3436 for 48 and 72 h. Cell proliferation was assessed
using the MTT assay. The percentage of cell growth inhibition was calculated by the absorption of control cells as 100 %. c MDA-MB-231 cells were treated
with various concentrations (0, 2.5, 5, 7.5, 10 and 15 μM) tamoxifen alone or in the presence of CSC-3436 (100, 200, and 400 nM) for 48 h. Cell proliferation was
assessed using the MTT assay. The percentage of cell growth inhibition was calculated by the absorption of control cells as 100 %. d MDA-MB-231 cells were
treated with CSC-3436 (200 nM) and tamoxifen (2.5 μM) alone or CSC-3436 (200 nM) plus tamoxifen (2.5 μM) for 48 h. Sub-G1 and G2/M phase were
assay by PI staining. *p < 0.05 compared with control group. e MDA-MB-231 cells were treated with CSC-3436 (200 nM) and tamoxifen
(2.5 μM) alone or CSC-3436 (200 nM) plus tamoxifen (2.5 μM) for 48 h followed by analysis of PARP and Caspase-3 by western blotting
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inhibition to CSC-3436 (20 mg/kg)-treated group. The
tumor weights had the similar results in tumor volume
inhibition (Fig. 6c). Thus, combination treatment of tam-
oxifen and CSC-3436 produced stronger tumor growth
inhibition in comparison to the CSC-3436 or tamoxifen
alone treatments.
Discussion
Current data suggest that autophagy targeted provide thera-
peutic benefits to patients. Failure to apoptosis induction in
cancer cells is one of main factor to cause chemotherapy re-
sistance. As cells fail to undergo apoptosis, some anti-
cancer agents such as etoposide could induce cell death by
autophagy. On the other words, failure to induce apoptosis
may drive cells undergo another cell death mechanism, au-
tophagy [29–31]. Besides, a number of studies have been
demonstrated that autophagy suppression enhances a result
of chemotherapy by increasing apoptosis [32–36]. However,
the relationship between autophagy and apoptosis in cell
death on cancer cells remains poorly understood.
Tamoxifen is one of highly successful adjuvant endo-
crine drug for over 30 year due to its abundant, mature
safety data in clinical [5] and function as an antagonist
via competition with estradiol to bind to ERα and modu-
lation of gene expression for ERα-positive breast cancer
cells [37, 38]. Although tamoxifen used for ERα-positive
breast cancer patients, it also shows therapeutic activity
in ERα-negative cancer [39, 40]. Other studies suggested
that a high dose of tamoxfein (approximately four fold
to eight fold higher than that for ERα-positive breast
cancers) exhibits anti-tumor activity in ERα-negative
cancer cells such as glioma, melanoma and pancreatic
carcinoma [41–43]. Besides to induced growth inhibition
and apoptosis, there have been increasing reports show-
ing that tamoxifen induced autophagy in breast and
colon cancer [8, 24]. Moreover, tamoxifen induced both
ERα-positive MCF-7 and ERα-negative SKBr-3 breast
cancer cells autophagy by LC3-II accumulation [8]. We
questioned whether tamoxifen also triggered autophagy
in TNBC cells. Our founding demonstrated that tamoxi-
fen induced endoplasmic reticulum stress (Fig. 3a and
b), and stimulation of AMPK/mTOR (Fig. 3c) signaling
to trigger autophagy (Fig. 1 and Fig. 2) but had non-
significant effect on cell growth inhibition (Fig. 4).
Next, we investigated the role of autophagy induced by
tamoxifen or CSC-3436 acted as a protective or pro-death
role. Inhibition of autophagy by using shRNA against
ATG-5, further increased cell growth inhibition, support-
ing both tamoxifen and CSC-3436-induced autophagy
played a protective role (Fig. 5a). ATG-5 is required for
the formation of autophagy and could be truncated to
fragment with a molecular mass of 24 kDa mediated by
calpain [44, 45]. The cleavage fragment activates caspase-
dependent cell death that has been considered to as a
contributor to the switch between autophagy and
apoptosis. Melanoma differentiation-associated gene 7
(mda-7)/interleukin-24 (IL-24) produced the cleavage of
ATG-5 by increasing calpain activity and resulted in au-
tophagy switch to apoptosis [23]. Similarly, our finding
demonstrated that CSC-3436 plus tamoxifen treatment
produced the cleavage of ATG5 (Fig. 5b).
Fig. 5 Relationship between autophagy and apoptosis induced by CSC-
3436 and tamoxifen. aMDA-MB-231 cells were transfectedwith the shATG5
and then treatedwith CSC-3436 (200 nM) and tamoxifen (2.5 μM) alone or
CSC-3436 (200 nM) plus tamoxifen (2.5 μM) for 24 h. Cell proliferationwas
assessed using theMTT assay. The percentage of cell growth inhibitionwas
calculated by the absorption of control cells as 100%. *p< 0.05 compared
with control group. MDA-MB-231 cells were treatedwith CSC-3436 (200
nM) and tamoxifen (2.5 μM) alone or CSC-3436 (200 nM) plus tamoxifen
(2.5 μM) for 48 h. The cleavage ofb tATG5 and c p-AMPK and p-mTOR and
β-actin were determined bywestern blotting
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Fig. 6 Effect of the combinational treatment with tamoxifen and CSC-3436 on tumor growth in MDA-MB-231 xenograft model. Each 5 week-old
nude mouse was performed by s. c. injection of MDA-MB-231 cells. Mice were randomly assigned to seven groups (n = 9), and oral administrations
treated with tamoxifen (2 mg/kg), CSC-3436 (10, 20 and 40 mg/kg, respectively) and the tamoxifen (2 mg/kg) plus CSC-3436 (5, 10, and
20 mg/kg, respectively). a Mean body weights, b mean tumor volumes, c tumor weights for each treatment group. *p < 0.05 compared
with vehicle-treated group
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Undendoplasmic reticulum stressful situations, au-
tophagy could be induced by multiple signaling path-
ways that related with cell growth, proliferation, survival
and death [11, 14]. The serine/threonine kinase mTOR
regulates cell survival and proliferation and also known
as a major negative regulator of autophagy. Upstream of
mTOR, AMPK is a metabolic sensor and activated by
low energy. It can inhibit mTOR and lead to autophagy
induction [46, 47]. Our finding demonstrated that CSC-
3436 decreased slightly tamoxifen-induced up-regulation
of p-AMPK protein expression. It may be another mech-
anism to enhance apoptosis (Fig. 5c).
Conclusions
Our founding demonstrated two ways which caused
CSC-3436 sensitized TNBC MDA-MB-231 breast cancer
cells to tamoxifen. CSC-3436 inhibited the effect of tam-
oxifen on p-AMPK and p-mTOR expressions and caused
ATG5-cleavaged which may contribute to autophagy
switch to apoptosis. As such, CSC-3436 combined with
tamoxifen may be a potential approach for treatment
ERα-negative breast cancer, and we suggest that this new
strategy be extensively explored.
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